Literature DB >> 19115513

Erlotinib for the treatment of non-small-cell lung cancer.

Meindert Boysen, Carole Longson, Andrew Stevens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19115513     DOI： 10.1016/s1470-2045(08)70283-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.

Authors:  Junshik Hong; Sun Young Kyung; Sang Pyo Lee; Jeong Woong Park; Sung Hwan Jung; Jae-Ik Lee; Se Hoon Park; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

2.  Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.

Authors:  Rui Feng; Sheng Yang
Journal:  J Int Med Res       Date:  2016-06-08       Impact factor: 1.671

3.  Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901.

Authors:  Li Dan; Ding Jian; Lin Na; Wang Xiaozhong
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.